As but one example, drugs that inhibit oligosaccharyltransferase, the enzyme that transfers oligosaccharides to proteins to facilitate folding, have shown promise in non–small cell lung cancer by selectively blocking EGFR (64). This evidence concerns the gene EGFR and lung cancer.